Literature DB >> 12162806

MDMX inhibits the p300/CBP-mediated acetylation of p53.

Peter Sabbatini1, Frank McCormick.   

Abstract

The p300/CBP-mediated acetylation of p53 significantly potentiates p53-mediated transactivation and growth inhibition. MDM2 inhibits the acetylation of p53 by p300/CBP through a mechanism that requires a stable p53-MDM2 interaction and that is sensitive to the deacetylase inhibitor, TSA. MDMX is an MDM2-like protein that shares with MDM2 the ability to interact with p53 and, in turn, inhibit p53-mediated transcription. It was therefore of interest to determine if MDMX could also inhibit the acetylation of p53 by p300/CBP. We demonstrate that MDMX dramatically inhibits the acetylation of p53 induced by both endogenous and ectopically expressed p300/CBP. We also demonstrate that the p53-binding domain of MDMX is required for the MDMX-mediated inhibition of p53 acetylation. Our results indicate that MDMX shares with MDM2 the ability to regulate a potentially important post-translational modification of p53. These results may have important biologic implications with respect to the MDMX-mediated regulation of p53 activity during development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162806     DOI: 10.1089/104454902320219077

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  22 in total

Review 1.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

2.  Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice.

Authors:  Hui Tian; Nicole R Tackmann; Aiwen Jin; Junnian Zheng; Yanping Zhang
Journal:  J Biol Chem       Date:  2017-11-09       Impact factor: 5.157

3.  Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage.

Authors:  Yaron Pereg; Dganit Shkedy; Petra de Graaf; Erik Meulmeester; Marina Edelson-Averbukh; Mogjiborahman Salek; Sharon Biton; Amina F A S Teunisse; Wolf D Lehmann; Aart G Jochemsen; Yosef Shiloh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-23       Impact factor: 11.205

Review 4.  p53 ubiquitination: Mdm2 and beyond.

Authors:  Christopher L Brooks; Wei Gu
Journal:  Mol Cell       Date:  2006-02-03       Impact factor: 17.970

5.  Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.

Authors:  Xiaolei Xie; Guangan He; Zahid H Siddik
Journal:  Mol Cancer Res       Date:  2016-12-28       Impact factor: 5.852

6.  Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity.

Authors:  Davide Danovi; Erik Meulmeester; Diego Pasini; Domenico Migliorini; Maria Capra; Ruth Frenk; Petra de Graaf; Sarah Francoz; Patrizia Gasparini; Alberto Gobbi; Kristian Helin; Pier Giuseppe Pelicci; Aart G Jochemsen; Jean-Christophe Marine
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

7.  MDM2 and MDMX: Alone and together in regulation of p53.

Authors:  Miriam Shadfan; Vanessa Lopez-Pajares; Zhi-Min Yuan
Journal:  Transl Cancer Res       Date:  2012-08       Impact factor: 1.241

Review 8.  Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?

Authors:  Danielly C F Costa; Guilherme A P de Oliveira; Elio A Cino; Iaci N Soares; Luciana P Rangel; Jerson L Silva
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-10-03       Impact factor: 10.005

Review 9.  MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.

Authors:  Jean-Christophe Marine; Aart G Jochemsen
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

10.  MDM4 (MDMX) and its Transcript Variants.

Authors:  F Mancini; G Di Conza; F Moretti
Journal:  Curr Genomics       Date:  2009-03       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.